Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Liana Makarian (NPI 1730495250)

Field	Value
Entity Type	Individual
Organization	Liana Makarian
Address	1705 E Broadway
City	Columbia
State	MO
ZIP	65201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 21, 2010

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

LIANA MAKARIAN’s billing is effectively single-payer: lifetime Medicare revenue is $3.3M and there is no Medicaid billing on file, so Medicare accounts for essentially all of the reported public-payer activity. This concentration means analyses of volume, payer risk, and reimbursement exposure should focus on Medicare reimbursement dynamics rather than dual-payer interactions.

Revenue is highly concentrated in a few high-cost oncology drugs: the precomputed top-3 Medicare codes account for 61.2% of this provider’s total Medicare revenue, anchored by J9271 ($1.1M, 35.6%), J9299 ($544.3K, 17.1%), and J0897 ($270K, 8.5%). This concentration indicates the practice’s financial performance is materially driven by a small set of immunotherapies and related injectables.

Clinical mix and service line represent a medical oncology/infusion operation: the top revenue drivers are oncology biologics (J9271, J9299, J0897) alongside chemotherapy administration (96413, 735 claims, $65.4K) and multiple supportive agents (J0881 darbepoetin, J2506 pegfilgrastim, J0185 aprepitant). The combination of high-volume injectable therapies and chemotherapy infusions is consistent with an outpatient oncology infusion practice that also bills office E/M services.

Competitive standing is mixed across specific codes: the provider ranks in the 95th percentile nationally for J0897 (rank #541 of 10057; labeled “notably above typical national volume”), and is also notably above typical volume for J0881 (rank #32 of 1114, 97th percentile) and 96413 (rank #229 of 7514, 97th percentile). Conversely, for leading immunotherapies J9271 (rank #193 of 1841, 89th percentile) and J9299 (rank #131 of 505, 74th percentile) the provider’s national standing is described as typical or unremarkable, indicating leadership in some supportive drug categories but only typical participation for certain high-cost immunotherapy agents.

Office-based E/M activity is unusually high relative to national peers: 99214 appears as an extreme outlier (1.6K claims, $144K, rank #3097 of 479517, 99th percentile), and 99213 is also notably above typical volume (645 claims, $38.7K, 96th percentile). High E/M volume alongside infusion billing suggests a practice that pairs frequent outpatient visits with ongoing treatment regimens, increasing the importance of ambulatory workflows and scheduling capacity.

Operational scale is reflected in large claim counts for some drugs but modest average reimbursement per claim: J9271 has 26.4K claims at $43 avg paid/claim and J9299 has 22.7K claims at $24 avg paid/claim, showing that revenue is produced through substantial administration volume rather than high per-claim payments. These volumes place the provider within typical national volume bands for those specific drugs while still producing sizable absolute revenue dollars.

Use of advanced diagnostics and specialized imaging is present but not dominant: the practice billed A9595 (piflufolastat f-18) for 99 claims ($48.3K, 1.5% of Medicare revenue) where it ranks low nationally (8th percentile), and billed 78815 PET/CT for 79 claims ($81.7K, 2.6% of Medicare revenue) at a typical national level (61st percentile). This pattern suggests access to or coordination with advanced PET imaging for oncology staging or management, but imaging is a smaller component of total revenue.

Tenure is established: the NPI was enumerated on 2010-08-21 (~16 years ago), indicating this is a long-standing practice entity. Combined with the concentration in immunotherapy and infusion services, the tenure supports interpretation that current billing patterns reflect an established oncology care model rather than a new or transient operation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

76 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,400	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	22,680	$20	$544.3K
J0897	Injection, denosumab, 1 mg	15,000	$20	$270K
J9173	Injection, durvalumab, 10 mg	3,820	$60	$236.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,580	$90	$144K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	64,670	$1	$129.3K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,560	$30	$87K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,030	$81.7K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	7,800	$10	$78K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	740	$90	$65.4K

Showing 1–10 of 76

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Liana Makarian — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

76 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	40	9,100	$40	$502K
J9299	2	20	14,170	$20	$360.3K
J9173	2	10	3,820	$60	$215.9K
J1568	4	10	2,900	$30	$103.8K
J0897	13	210	2,400	$20	$82.4K
J9264	5	10	6,500	$10	$69.9K
J0881	1	10	15,500	$1	$63.1K
A9595	2	10	100	$490	$52.7K
Q5119	5	10	1,570	$20	$43.6K
J1437	2	10	2,500	$20	$43.5K

Showing 1–10 of 76

Related Providers

Other providers that share a Tax Identification Number (TIN) with Liana Makarian, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Umasankar Ramadoss	MO	Hematology & Oncology Physician	$3.3M	$0
Mark Tungesvik	MO	Hematology & Oncology Physician	$3.3M	$0
Elangovan Balakrishnan	MO	Hematology & Oncology Physician	$3.1M	$0
Andrew Iliff	MO	Hematology & Oncology Physician	$2.8M	$0
Mark Bryer	MO	Radiation Oncology Physician	$638K	$0
Reed Cope	MO	Radiation Oncology Physician	$572.2K	$0
Alexandre Tungesvik	MO	Hematology & Oncology Physician	$569.8K	$0
Harold Johnson	MO	Radiation Oncology Physician	$542.5K	$0
Hunter Nolen	MO	Urology Physician	$359.5K	$0
Andrew Leiker	MO	Radiation Oncology Physician	$303.9K	$0

Nearby Providers

Other providers in the same ZIP code as Liana Makarian, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodhaven	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$88.3M
Palmer's Home Care, LLC	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$82.3M
Oats, Inc.	MO	Non-emergency Medical Transport (VAN)	$0	$23.4M
Independent Living Center Of Mid-missouri Inc.	MO	Specialist	$0	$14.2M
Ch Allied Services, Inc.	MO	General Acute Care Hospital	$0	$8.6M
Central Missouri Area Agency On Aging	MO	Voluntary or Charitable Agency	$0	$8.4M
Life Christain Outreach	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.1M
Surgical Center At Columbia Orthopaedic Group LLC	MO	Ambulatory Surgical Clinic/Center	$6.2M	$0
Mid-missouri Supported Living	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$5.3M
Woodhaven Learning Center	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$5.1M

Liana Makarian — Billing Profile & Reimbursement Data

Sign up for Liana Makarian — Billing Profile & Reimbursement Data policy alerts

Liana Makarian — Billing Profile & Reimbursement Data

Sign up for Liana Makarian — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References